Insider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Purchases 3,605 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano acquired 3,605 shares of the stock in a transaction on Monday, December 30th. The shares were acquired at an average price of $4.49 per share, for a total transaction of $16,186.45. Following the acquisition, the director now owns 7,807 shares of the company’s stock, valued at approximately $35,053.43. The trade was a 85.79 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Precision BioSciences Trading Up 1.3 %

NASDAQ:DTIL opened at $4.75 on Friday. Precision BioSciences, Inc. has a one year low of $3.61 and a one year high of $19.43. The company has a market cap of $36.44 million, a PE ratio of 79.18 and a beta of 1.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The firm has a 50-day moving average of $6.44 and a 200-day moving average of $8.44.

Institutional Trading of Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC increased its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 702,069 shares of the company’s stock after buying an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent quarter. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.